



available at www.sciencedirect.com
journal homepage: www.europeanurology.com



European Association of Urology

Corrigendum

Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” [Eur Urol 2018;73:462–8]

Jose Luis Perez-Gracia^{a,*}, Yohann Loriot^b, Jonathan E. Rosenberg^c, Thomas Powles^d, Andrea Necchi^e, Syed A. Hussain^f, Rafael Morales-Barrera^g, Margitta M. Retz^h, Günter Niegischⁱ, Ignacio Durán^j, Christine Théodore^k, Enrique Grande^l, Xiaodong Shen^m, Jingjing Wang^m, Betty Nelson^m, Christina L. Derleth^m, Michiel S. van der Heijdenⁿ

^a Clínica Universidad de Navarra, Pamplona, Spain; ^b Gustave Roussy, Université Paris-Saclay, Département de Médecine, Villejuif, France; ^c Memorial Sloan Kettering Cancer Center, New York, NY, USA; ^d Barts Cancer Institute, Queen Mary University of London, London, UK; ^e Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; ^f Plymouth University, Peninsula Schools of Medicine and Dentistry, Plymouth University Hospitals NHS Trust, Devon, UK; ^g Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; ^h Urologische Klinik und Poliklinik, Technical University Munich, Munich, Germany; ⁱ Department of Urology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; ^j Instituto de Biomedicina de Sevilla, IBIS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain; ^k Department of Oncology, Hôpital Foch, Suresnes, France; ^l Hospital Universitario Ramón y Cajal, Madrid, Spain; ^m Genentech, Inc., South San Francisco, CA, USA; ⁿ Netherlands Cancer Institute, Amsterdam, The Netherlands

A review of potential conflicts of interest for all the authors in relation to this study revealed further items that Rafael Morales-Barrera and Enrique Grande wish to disclose. The conflicts of interest statement with full disclosures is therefore as follows.

Financial disclosures: Jose Luis Perez-Gracia certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Jose Luis Perez-Gracia has received grants or funding from Roche, had consultancies with Roche, and received honoraria from Roche. Yohann Loriot has received grants from Sanofi and fees for consulting or advisory roles from Astellas, AstraZeneca, Janssen, MSD, Roche, and Sanofi. Jonathan E. Rosenberg has received grants or funding from Bristol-Myers Squibb and Roche and has had consultancies with Agensys, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, EMD-Serono, Merck, Roche, and Seattle Genetics. Thomas Powles has received grants or funding from AstraZeneca and Roche and received honoraria from AstraZeneca, Bristol-Myers Squibb, Merck, and Roche. Andrea Necchi has received grants or funding from Amgen, AstraZeneca, and Merck & Co. Inc., had consultancies with Astellas/Seattle Genetics, AstraZeneca, Bayer, Merck & Co. Inc., Pfizer, and Roche, and received honoraria from Merck & Co. Inc., Pierre Fabre, and PeerVoice Roche. Syed A. Hussain has attended advisory board meetings with AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, Merck, Pierre Fabre, and Roche and received educational grants and institutional funding from Cancer Research UK, Boehringer Ingelheim, Janssen, and Eli Lilly. Morales-Barrera has no financial disclosures. Margitta M. Retz is employed by and affiliated with Technical University Munich, Germany Klinikum rechts der Isar, Department of Urology. Günter Niegisch has received grants or funding from 4SC AG, had consultancies with Bristol-Myers Squibb, IMS Health AG, medac GmbH, and

DOI of original article: <https://doi.org/10.1016/j.eururo.2017.11.023>.

* Corresponding author. Department of Oncology, University Clinic of Navarra, Avda. Pio XII, 36, 31008 Pamplona, Spain. Tel. +34 948 255 400; Fax: +34 948 255 500.

E-mail address: jlgracia@unav.es (J.L. Perez-Gracia).

<https://doi.org/10.1016/j.eururo.2018.11.032>

0302-2838/© 2018 Published by Elsevier B.V. on behalf of European Association of Urology.



Roche Pharma AG and received honoraria from Pfizer Pharma GmbH, Pierre Fabre Pharma GmbH, and Roche Pharma AG. Ignacio Durán has received grants or funding from Roche-Genentech, had consultancies with Bristol-Myers Squibb, Merck Sharp & Dohme Corp, and Roche-Genentech, and received honoraria from Merck Sharp & Dohme Corp, Pierre Fabre, and Roche. Christine Théodore has no financial disclosures. Betty Nelson, Xiaodong Shen, and Christina L. Derleth are employed by Genentech and own Roche stock. Jingjing Wang is a consultant of Genentech. Michiel S.van der Heijden has received grants or funding from Astellas and had consultancies with Astellas, AstraZeneca, Bristol-Myers Squibb, and Roche-Genentech. Rafael Morales-Barrera has received speaker honoraria or travel support from Bayer, Roche, Astellas, Janssen-Cilag, MSD, and Sanofi-Aventis. Enrique Grande has received honoraria for advisory boards, meetings, and/or lectures from Pfizer, BMS, IPSEN, Roche, Eisai, Eusa Pharma, MSD, Sanofi-Genzyme, Adacap, Novartis, Pierre Fabre, Lexicon, and Celgene, and has received unrestricted research grants from Pfizer, AstraZeneca, MTEM/Threshold, Roche, IPSEN, and Lexicon.